Figures & data
Figure 1. Functional assays of Ki-CA patient tumor derived cells’ response to molecular targeted small-molecule kinase inhibitors. Two thousand cells in medium without EGF were added to 96-well plates containing each small-molecule inhibitor at four serial dilutions spanning a concentration range that includes the predicted IC50, incubated at 37°C for three days and assayed by MTS (Promega). The viability data were adjusted for wells with no cells/inhibitor, and normalized to untreated wells of the cultured cells (OD value for wells with cells without drug treatment = 100% cell viability) and to a database of cell lines and tumor samplesCitation4 to yield responses and the IC50 in nM for each agent. IC50 values less than 20% of the global median (shown as 100%) are considered responses and are well within clinically achievable concentrations.
![Figure 1. Functional assays of Ki-CA patient tumor derived cells’ response to molecular targeted small-molecule kinase inhibitors. Two thousand cells in medium without EGF were added to 96-well plates containing each small-molecule inhibitor at four serial dilutions spanning a concentration range that includes the predicted IC50, incubated at 37°C for three days and assayed by MTS (Promega). The viability data were adjusted for wells with no cells/inhibitor, and normalized to untreated wells of the cultured cells (OD value for wells with cells without drug treatment = 100% cell viability) and to a database of cell lines and tumor samplesCitation4 to yield responses and the IC50 in nM for each agent. IC50 values less than 20% of the global median (shown as 100%) are considered responses and are well within clinically achievable concentrations.](/cms/asset/c6c9ed89-6f86-4c4e-b4b3-11412ee40231/kcbt_a_10922960_f0001.gif)
Figure 2. Dose responses of Ki-CA patient derived cell line to selected drugs. Cells were added to 96-well plates containing each small-molecule inhibitor at 11 serial dilutions spanning a concentration range that includes the predicted IC50 and evaluated as in . Values shown are mean ± SD for triplicate wells. Best fit curves were generated using GraphPad Prism software.
![Figure 2. Dose responses of Ki-CA patient derived cell line to selected drugs. Cells were added to 96-well plates containing each small-molecule inhibitor at 11 serial dilutions spanning a concentration range that includes the predicted IC50 and evaluated as in Figure 1. Values shown are mean ± SD for triplicate wells. Best fit curves were generated using GraphPad Prism software.](/cms/asset/965fa618-589c-4b6b-9321-6e9f248a9eb1/kcbt_a_10922960_f0002.gif)
Figure 3. Primary Ki-CA patient tumor immunohistochemistry. Tumor exhibited both Src positivity (A) and VHL positivity (B). Power: 20 × ; Scale bar: 20 μM
![Figure 3. Primary Ki-CA patient tumor immunohistochemistry. Tumor exhibited both Src positivity (A) and VHL positivity (B). Power: 20 × ; Scale bar: 20 μM](/cms/asset/620da7a7-0b30-4293-adff-e1ee38670496/kcbt_a_10922960_f0003.gif)